Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout

Neuromuscular Disorders

Volumn 17, Issue 5, 2007, Pages 376-384

  Golumbek, Paul T ^a   Keeling, Richard M ^a   Connolly, Anne M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; Fatigue; Immunoglobulin; mdx mouse; Prednisolone; RAG2 knockout; Strength; T cell; Voluntary wheel running

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; DYSTROPHIN; IMMUNOGLOBULIN; PREDNISOLONE; RAG2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CALCIFICATION; CELL FUNCTION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GRIP STRENGTH; MALE; MEASUREMENT; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; STRENGTH; T LYMPHOCYTE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; CREATINE KINASE; DNA-BINDING PROTEINS; FEMALE; FORELIMB; GLUCOCORTICOIDS; IMMUNOGLOBULINS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, ANIMAL; PREDNISOLONE; PSYCHOMOTOR PERFORMANCE;

EID: 34247647576     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2007.02.005     Document Type: Article

References (65)

1. Balaban B., Matthews D.J., Clayton G.H., and Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 84 11 (2005) 843-850
2. Biggar W.D., Harris V.A., Eliasoph L., and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 4 (2006) 249-255
3. Lefaucheur J.P., Pastoret C., and Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242 1 (1995) 70-76
4. Connolly A.M., Keeling R.M., Mehta S., Pestronk A., and Sanes J.R. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 11 8 (2001) 703-712
5. Keeling R.M., Golumbek P.T., Streif E.M., and Connolly A.M. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve (2006)
6. Arahata D., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16 (1984) 193-208
7. Gorospe J.R., Tharp M.D., Hinckley J., Kornegay J.N., and Hoffman E.P. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122 1 (1994) 44-56
8. Arahata K., and Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 23 2 (1988) 168-173
9. McDouall R.M., Dunn M.J., and Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 99 2-3 (1990) 199-217
10. Isenberg D.A. Immunoglobulin deposition in skeletal muscle in primary muscle diseases. Q J Med 52 207 (1983) 297-310
11. Spuler S., and Engel A.G. Unexpected sarcolemmal complement membrane attack complex deposits on non necrotic muscle fibers in muscular dystrophies. Neurology 50 1 (1998) 41-46
12. Sewry C.A., Dubowitz V., Abraha A., Luzio J.P., and Campbell A.K. Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J Neurol Sci 81 2-3 (1987) 141-153
13. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 10 (2002) 917-925
14. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation of Duchenne muscular dystrophy; interesting results in a trial of prednisone. Arch Neurol 44 (1987) 812-817
15. Fenichel G.M., Mendell J.R., Moxley R.T., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991) 575-579
16. Kissel J.T., Lynn d.J., Rammohan K.W., et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 43 (1993) 532-536
17. Backman E., and Henriksson K.G. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 5 3 (1995) 233-241
18. Griggs R.C., Moxley III R.T., Mendell J.R., et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical investigation of Duchenne dystrophy group. Arch Neurol 48 4 (1991) 383-388
19. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320 24 (1989) 1592-1597
20. Kinali M., Mercuri E., Main M., Muntoni F., and Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 12 Suppl. 1 (2002) S169-S174
21. Pradhan S., Ghosh D., Srivastava N.K., et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253 10 (2006) 1309-1316
22. Yilmaz O., Karaduman A., and Topaloglu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol 11 8 (2004) 541-544
23. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 17 Suppl (1995) 39-43
24. Campbell C., and Jacob P. Deflazacort for the treatment of Duchenne dystrophy: a systematic review. BMC Neurol 3 1 (2003) 7
25. Sharma D.R., Mynhier M.A., and Miller R.G. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 43 (1993) 527-532
26. Stupka N., Gregorevic P., Plant D.R., and Lynch G.S. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol (Berl) 107 4 (2004) 299-310
27. Kissel J.T., Lynn D.J., Rammohan K.W., et al. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 43 3 Pt 1 (1993) 532-536
28. Griggs R.C., Moxley III R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43 3 Pt 1 (1993) 520-527
29. Morrison J., Lu Q.L., Pastoret C., Partridge T., and Bou-Gharios G. T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest 80 6 (2000) 881-891
30. Spencer M.J., and Tidball J.G. Immune cell contribution to mdxdystrophy. Muscle Nerve 7 (1998) S193
31. Chang W.J., Iannaccone S.T., Lau K.S., et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA 93 17 (1996) 9142-9147
32. Spencer M.J., Croall D.E., and Tidball J.G. Calpains are activated in necrotic fibers from mdx dystrophic mice. J Biol Chem 270 18 (1995) 10909-10914
33. Spencer M.J., Montecino-Rodriguez E., Dorshkind K., and Tidball J.G. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98 2 (2001) 235-243
34. Spencer M.J., Marino M.W., and Winckler W.M. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 10 8 (2000) 612-619
35. Spencer M.J., and Tidball J.G. Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul Disord 11 6-7 (2001) 556-564
36. Cai B., Spencer M.J., Nakamura G., Tseng-Ong L., and Tidball J.G. Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol 156 5 (2000) 1789-1796
37. Shinkai Y., Rathbun G., Lam K.P., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68 5 (1992) 855-867
38. Amalfitano A., and Chamberlain J.S. The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve 19 12 (1996) 1549-1553
39. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835 1 (1999) 18-26
40. Al-Lozi M.T., Pestronk A., Yee W.C., Flaris N., and Cooper J. Rapidly evolving myopathy with myosin-deficient muscle fibers. Ann Neurol 35 (1994) 273-279
41. Connolly A.M., Pestronk A., Planer G.J., Yue J., Mehta S., and Choksi R. Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining. Neurology 46 (1996) 810-814
42. Connolly A.M., Pestronk A., Mehta S., and Al-Lozi M. Case of the month: primary α-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve 21 (1998) 1549-1553
43. Nevo Y., and Pestronk A. Neonatal perifasciular myopathy. Pediatr Neurol 15 (1996) 150-152
44. Planer G.J., Pestronk A., Kaiser K.K., and Brooke M.H. ATPase stain in muscle histochemistry. Muscle Nerve (1992)
45. Hayes A., and Williams D.A. Beneficial effects of voluntary wheel running on the properties of dystrophic mouse muscle. J Appl Physiol 80 2 (1996) 670-679
46. Connolly A.M., Keeling R.M., Streif E.M., Pestronk A., and Mehta S. Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin alpha2-deficient mice. J Neuroimmunol 127 1-2 (2002) 80-87
47. Golumbek PT, Keeling RM, Connolly AM. RAG-2 gene knockout in mice causes fatigue, submitted for publication.
48. Roozendaal R., and Carroll M.C. Emerging patterns in complement-mediated pathogen recognition. Cell 125 1 (2006) 29-32
49. Liu J.M., Okamura C.S., Bogan D.J., Bogan J.R., Childers M.K., and Kornegay J.N. Effects of prednisone in canine muscular dystrophy. Muscle Nerve 30 6 (2004) 767-773
50. Bakay M., Zhao P., Chen J., and Hoffman E.P. A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord 12 Suppl 1 (2002) S125-S141
51. Muntoni F., Fisher I., Morgan J.E., and Abraham D. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord 12 Suppl 1 (2002) S162-S165
52. Nguyen H.H., Jayasinha V., Xia B., Hoyte K., and Martin P.T. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 99 8 (2002) 5616-5621
53. Gillis J.M. Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse. Neuromuscul Disord 12 Suppl 1 (2002) S90-S94
54. Moghadaszadeh B., Albrechtsen R., Guo L.T., et al. Compensation for dystrophin-deficiency: ADAM12 overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins. Hum Mol Genet 12 19 (2003) 2467-2479
55. Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., and Kaufman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 152 6 (2001) 1207-1218
56. Fisher I., Abraham D., Bouri K., Hoffman E.P., Muntoni F., and Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 19 7 (2005) 834-836
57. Kolodziejczyk S.M., Walsh G.S., Balazsi K., et al. Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol 11 16 (2001) 1278-1282
58. St-Pierre S.J., Chakkalakal J.V., Kolodziejczyk S.M., Knudson J.C., Jasmin B.J., and Megeney L.A. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 18 15 (2004) 1937-1939
59. Chakkalakal J.V., Harrison M.A., Carbonetto S., Chin E., Michel R.N., and Jasmin B.J. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet 13 4 (2004) 379-388
60. De Luca A., Nico B., Liantonio A., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166 2 (2005) 477-489
61. Messina S., Bitto A., Aguennouz M., et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 198 1 (2006) 234-241
62. Saccani S., Saccani A., Varesio L., Ghosh P., Young H.A., and Sica A. Divergent effects of dithiocarbamates on AP-1-containing and AP-1-less NFAT sites. Eur J Immunol 29 4 (1999) 1194-1201
63. Wehling-Henricks M., Lee J.J., and Tidball J.G. Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord 14 8-9 (2004) 483-490
64. Hodgetts S., Radley H., Davies M., and Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF alpha function with Etanercept in mdx mice. Neuromuscul Disord (2006)
65. Guerette B., Asselin I., Vilquin J.T., Roy R., and Tremblay J.P. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. Muscle Nerve 18 1 (1995) 39-51